# Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients

> **NCT00978237** · PHASE4 · COMPLETED · sponsor: **Juan A. Arnaiz** · enrollment: 20 (actual)

## Conditions studied

- HIV Infections
- Lipoatrophy

## Interventions

- **DRUG:** EFV
- **DRUG:** LPV/r

## Key facts

- **NCT ID:** NCT00978237
- **Lead sponsor:** Juan A. Arnaiz
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00978237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00978237, "Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00978237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*